Lifecore Receives Approval to Market Stage-1 Dental Implant System in Japan.Business Editors & Health/Medical Writers CHASKA, Minn.--(BUSINESS WIRE)--Jan. 9, 2002 LIFECORE BIOMEDICAL bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. , INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic. Antonym: dec. . (Nasdaq:LCBM) announced today that it has received approval from the Japanese Ministry of Health and Welfare The Ministry of Health and Welfare is a branch of the government of South Korea. External links
• • to market the STAGE-1(TM) RDS (1) (Remote Data Services) A set of programming interfaces from Microsoft that enables users to update data on the Internet or intranets from their ActiveX-enabled browser. Single Stage TPS (1) (Transactions Per Second) The number of transactions processed within one second. TPS is a better rating for the performance of hardware and software than the common MHz and GHz rating of the computer. Dental Implant System ("Stage-1") in Japan. This Stage-1 implant represents the first single stage implant model that Lifecore's Oral Restorative Division will be marketing in Japan. The Company expects to expand its Japanese implant offerings with subsequent approvals. The current approval follows a similar approval in Korea last September and represents a continuation of the Company's strategy to increase the sales of its products in the Asian marketplace. The Japanese dental implant market was valued at $69.6 million in 2001 by the Millennium Research Group of Toronto. The market grew 12.3 percent over 2000. While several types of implants are sold in Japan, the TPS (titanium plasma spray) coated implants are the dominant style preferred by Japanese implant dentists. Lifecore's distributor in Japan is the Hakusui Trading Company, Ltd. Lifecore President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Jim Bracke, commented: "We are pleased to have completed the long regulatory approval process for our successful Stage-1 product in Japan, expanding our penetration of the Asian market. The demographics of the Asian marketplace strongly favor continued growth in implant dentistry". Certain statements in this release are forward-looking statements as defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Statements implying timing, outcome, or the extent of marketing success with the new Japanese product are subject to change. Because of numerous risks and uncertainties in the complex regulatory and competitive aspects of Lifecore's business activity, actual results may differ materially from those implied. Investors are strongly cautioned to review more detailed discussions of those risks presented in the Company's reports on Forms 10-Q and 10-K. Lifecore Biomedical develops, manufactures, and markets biomaterials and medical devices for use in various surgical markets. Additional general corporate information is available on the Internet at http://www.lifecore.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion